SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Orchid Pharma - Quaterly Results

14 Nov 2022 Evaluate
The sales surged to Rs. 1652.50 millions, up 35.55% for the September 2022 quarter as against Rs. 1219.08 millions during the corresponding quarter previous year.The Net Loss for the quarter ended September 2022 is Rs. -33.22 millions as compared to Net Loss of Rs. -207.43 millions of corresponding quarter ended September 2021Operating profit for the quarter ended September 2022 rose to 236.63 millions as compared to 92.12 millions of corresponding quarter ended September 2021.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202209 202109 % Var 202209 202109 % Var 202203 202103 % Var
Sales 1652.50 1219.08 35.55 2962.38 2174.45 36.24 5569.74 4506.95 23.58
Other Income 58.39 17.67 230.45 87.70 48.90 79.35 90.03 64.61 39.34
PBIDT 236.63 92.12 156.87 390.44 167.81 132.67 662.62 643.62 2.95
Interest 92.21 98.93 -6.79 170.61 207.72 -17.87 320.12 513.36 -37.64
PBDT 144.42 -6.81 -2220.70 219.83 -39.91 -650.81 342.50 130.26 162.94
Depreciation 177.64 200.62 -11.45 393.93 401.70 -1.93 870.21 1088.99 -20.09
PBT -33.22 -207.43 -83.98 -174.10 -441.61 -60.58 -527.71 -958.73 -44.96
TAX 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Deferred Tax 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
PAT -33.22 -207.43 -83.98 -174.10 -441.61 -60.58 -527.71 -958.73 -44.96
Equity 408.16 408.16 0.00 408.16 408.16 0.00 408.16 408.16 0.00
PBIDTM(%) 14.32 7.56 89.50 13.18 7.72 70.78 11.90 14.28 -16.69

Orchid Pharma Share Price

570.50 6.40 (1.13%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×